C5 and hemolytic-uremic syndrome: One SPK developed pancreas allograft failure and was subsequently initiated on belatacept for the remaining kidney allograft.  Two SPK recipients were excluded because they also received complement C5 blocking agents (eculizumab and ravulizumab) for atypical HUS.